What is Endostim?
Endostim is at the forefront of developing a novel neurostimulation treatment system designed to manage gastroesophageal reflux disease (GERD), a chronic digestive disorder impacting a substantial global population. The company's proprietary EndoStim System aims to offer a long-term solution for reflux control by employing mild electrical stimulation to the lower esophageal sphincter. While currently limited to investigational use in the United States, EndoStim is strategically targeting patients with GERD that is refractory to conventional drug therapies, with the ultimate goal of enhancing patient quality of life.
How much funding has Endostim raised?
Endostim has raised a total of $94.6M across 12 funding rounds:
Private Equity
$5.5M
Private Equity
$14.1M
Series C
$9.1M
Unspecified
$11.2M
Private Equity
$6.4M
Private Equity
$2.5M
Series D
$25M
Private Equity
$12.1M
Private Equity (2011): $5.5M, investors not publicly disclosed
Private Equity (2012): $14.1M, investors not publicly disclosed
Series C (2013): $9.1M led by Prolog Ventures and Billiken Angels Network
Unspecified (2013): $11.2M, investors not publicly disclosed
Private Equity (2014): $6.4M, investors not publicly disclosed
Private Equity (2015): $2.5M, investors not publicly disclosed
Series D (2016): $25M with participation from Wellington Partners, Sante Ventures, Gimv, and Endeavour Vision
Private Equity (2017): $12.1M, investors not publicly disclosed
Key Investors in Endostim
Prolog Ventures
Prolog Ventures is a venture capital firm that invests in startups dedicated to promoting healthy living and sustainability. Their portfolio includes companies that produce premium beverages, healthy food options, innovative agricultural solutions, and wellness services. They aim to support businesses that contribute to a healthier lifestyle and a healthier planet. Their intended clients are startups in the health and wellness sector.
Billiken Angels Network
The Billiken Angels Network, affiliated with Saint Louis University, invests in businesses connected to the university, aiming to provide expertise and capital to promising firms. Recognized as one of the top angel groups in the Plains States, they focus on making a positive impact on the economy and region. Currently, the network is fully invested and not seeking new opportunities, but they offer resources and education for current and future businesses. Their mission encompasses supporting firms across all industries and stages of development.
Sante Ventures
Santé is a privately held investment firm that focuses on innovative healthcare and technology companies, managing over $1 billion in capital. The company primarily invests in the Biotech, Medtech, and Healthtech sectors through its Santé Ventures division, seeking visionary entrepreneurs and ideas that can enhance patient health outcomes. Additionally, Santé Capital employs a proprietary software called MindRank to identify investment opportunities in publicly traded securities using advanced data science and machine learning techniques. Their goal is to generate attractive risk-adjusted returns while contributing to advancements in healthcare.
What's next for Endostim?
The recent major strategic investment in Endostim signals a pivotal moment for the company, likely enabling it to advance its clinical trials, pursue regulatory approvals, and scale its commercialization efforts. This capital infusion, coupled with the backing of experienced investors in the healthcare technology and venture capital space, positions Endostim to further its mission of providing a first-in-class neurostimulation treatment for GERD. The company's focus on drug-refractory GERD patients suggests a clear path toward addressing a significant unmet medical need, potentially leading to substantial market penetration and improved patient outcomes.
See full Endostim company page
